PS-QD Phase3 Clinical Study -Investigation to find new dosage and administration of mesalazine for the treatment of patients with Ulcerative Colitis in remission phase.

Phase 3

• Conditions: ulcerative colitis

• Registration Number: JPRN-jRCT2080220935
• Lead Sponsor: Kyorin Pharmaceutical Co.,LTD

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-12-09
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Patients meet the following criteria are to be enrolled in this study.
-Patients who were diagnosed with ulcerative colitis.
-Those who are in remission state when investigational drug is initially administered.
etc.

Exclusion Criteria

Patients are not to be eligible for the study when they will fall into any of the following criteria.
-Those who have a history of drug hypersensitivity to mesalazine or salicylic acid series
-Those who have a history of serious hepatic and/or renal disorder, or those who are with serious hepatic and/or renal disorder
-Those who have a history of serious cardiac, pulmonary, blood and/or pancreatic disorder, or those who are with serious cardiac, pulmonary, blood and/or pancreatic disorder
etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified